Ultragenyx said its experimental therapy for Angelman syndrome, a rare disease, showed no benefit compared to a sham treatment in a Phase 3 trial.
BriefSTAT News
STAT+: Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial
